Head-To-Head Comparison: Elicio Therapeutics (NASDAQ:ELTX) vs. Cardiff Oncology (NASDAQ:CRDF)

Elicio Therapeutics (NASDAQ:ELTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Elicio Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Cardiff Oncology	-7,885.43%	-93.24%	-68.74%

Volatility & Risk

Elicio Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Insider and Institutional Ownership

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Elicio Therapeutics and Cardiff Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.40)	-1.28
Cardiff Oncology	$590,000.00	129.61	-$45.85 million	($0.67)	-1.47

Elicio Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Elicio Therapeutics and Cardiff Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	1	4	0	2.50
Cardiff Oncology	1	4	2	0	2.14

Elicio Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 543.32%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 662.97%. Given Cardiff Oncology’s higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Elicio Therapeutics.

Summary

Elicio Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.